COVID-19 in a patient with systemic sclerosis treated with tocilizumab for SSc-ILD

Ann Rheum Dis. 2020 May;79(5):668-669. doi: 10.1136/annrheumdis-2020-217442. Epub 2020 Apr 2.

Authors

Carina Mihai¹, Rucsandra Dobrota¹, Maria Schröder¹, Alexandru Garaiman¹, Suzana Jordan¹, Mike Oliver Becker¹, Britta Maurer¹, Oliver Distler²

Affiliations

¹ Department of Rheumatology, University Hospital Zurich, Zurich, Switzerland.
² Department of Rheumatology, University Hospital Zurich, Zurich, Switzerland oliver.distler@usz.ch.

PMID: 32241792
DOI: 10.1136/annrheumdis-2020-217442

No abstract available

Keywords: biological therapy; communicable diseases, imported; cytokines; pulmonary fibrosis; scleroderma, systemic.

Publication types

Case Reports
Letter

MeSH terms

Antibodies, Monoclonal, Humanized / therapeutic use*
Betacoronavirus*
COVID-19
Coronavirus Infections / complications*
Cough / etiology
Female
Humans
Middle Aged
Pandemics
Pneumonia, Viral / complications*
SARS-CoV-2
Scleroderma, Systemic / complications
Scleroderma, Systemic / drug therapy*

Substances

Antibodies, Monoclonal, Humanized
tocilizumab